25 June, 2017
About 187,230 shares traded. Lion Biotechnologies Inc (NASDAQ:LBIO) has risen 13.28% since June 16, 2016 and is uptrending. Out of 2 Wall Street analysts rating Lion Biotech, 2 give it "Buy", 0 "Sell" rating, while 0 recommend "Hold". Therefore 24% are positive. Netapp Inc. had 88 analyst reports since August 17, 2015 according to SRatingsIntel.
11/23/2016 - Lion Biotechnologies Inc had its "buy" rating reiterated by analysts at Roth Capital. The stock of Brandywine Realty Trust (NYSE:BDN) has "In-Line" rating given on Monday, May 15 by Evercore. (NASDAQ:NTAP). Brown Brothers Harriman & Com holds 0% or 4,021 shares in its portfolio. The company now has an average rating of "Buy" and a consensus target price of $15.17. The firm has "Market Perform" rating given on Thursday, April 6 by JMP Securities. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.
At the end of 03/31/2017 reporting period, 36 institutional holders increased their position in Lion Biotechnologies, Inc. 12 funds opened positions while 32 raised stakes. Geode Capital Management LLC now owns 500,764 shares of the biotechnology company's stock valued at $3,730,000 after buying an additional 142,298 shares during the period. Tower Capital Ltd Liability (Trc) invested in 0% or 4,721 shares. 149,885 are held by Tiaa Cref Investment Ltd Liability Corp. Finally, Geode Capital Management LLC increased its stake in Lion Biotechnologies by 39.7% in the first quarter. Schwab Charles Management reported 196,150 shares stake.
Several analysts have released their opinion on Lion Biotechnologies, Inc. Wells Fargo & Company started coverage on Lion Biotechnologies in a research note on Friday, March 17th. Atlantic Tru Gru Ltd accumulated 0% or 43,000 shares. On the other hand, adjusted net loss for the quarter widened to $17.39 million, or $0.28 a share from a loss of $5.10 million or $0.10 a share, a year ago. Lion Biotechnologies Inc has a 52-week low of 4.90 and a 52-week high of 9.58.
06/06/2016 - Lion Biotechnologies Inc was downgraded to "neutral" by analysts at SunTrust. Hightower Advisors Llc sold 30,691 shares as Netapp Inc (NTAP)'s stock declined 1.59%. Earnest Ltd reported 0% of its portfolio in NetApp Inc.
Lion Biotechnologies, Inc.is a clinical-stage biopharmaceutical company. The stock's market cap is $414.63 million. The Company is focused on the development and commercialization of cancer immunotherapy products created to harness the power of a patient's own immune system to eradicate cancer cells. It now has negative earnings. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. Jefferies Group LLC restated a buy rating and issued a $11.00 price target on shares of Lion Biotechnologies in a research note on Thursday, May 18th. The firm has "Buy" rating given on Thursday, October 8 by Chardan Capital Markets. Lion Biotechnologies, Inc.is now trading 10.18% above its 20-day and -5.49% versus the 200-day simple moving averages while 6.49% compared with its 50-day simple moving average. They expect $-0.34 EPS, down 47.83% or $0.11 from last year's $-0.23 per share. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.05.
Investors sentiment increased to 0.95 in 2016 Q4. Its up 0.11, from 0.84 in 2016Q3. On Tuesday, December 29 the stock rating was maintained by Monness Crespi & Hardt with "Sell".
Institutional investors now hold around $305 million or 81.6% in LBIO stock. It dived, as 37 investors sold NTAP shares while 159 reduced holdings. National Bank Of America Corp De stated it has 787,312 shares or 0.01% of all its holdings. Ghost Tree Capital Llc, a New York-based fund reported 975,000 shares.#img1#. Tokio Marine Asset Mgmt Limited holds 7,219 shares.
Multiple company employees have indulged in significant insider trading. Barings Real Advisers Limited Liability Co, Connecticut-based fund reported 58,343 shares. Another trade for 9,027 shares valued at $153,559 was sold by DEVUONO H JEFFREY.
